Daniel Unić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Unić has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Igor Rudež
Department of Cardiac and Transplant Surgery, University Hospital Dubrava, Zagreb, Croatia
38 shared publications - Davor Barić
Department of Cardiac and Transplant Surgery, Dubrava University Hospital, 10000 Zagreb, Croatia
26 shared publications - Savica Gjorgjievska
Department of Cardiac and Transplant Surgery, Dubrava University Hospital, 10000 Zagreb, Croatia
25 shared publications - Šime Manola
Dubrava University Hospital, Zagreb, Croatia
22 shared publications - Ivana Jurin
Department of Cardiovascular Diseases, University Hospital Dubrava, Zagreb, Croatia
20 shared publications - Irzal Hadžibegović
Department of Cardiovascular Diseases, University Hospital Dubrava, 10000 Zagreb, Croatia
19 shared publications
Latest Publications
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 279
Beyond survival: determinants of a composite one-year outcome of survival, functional status and cognitive integrity after transcatheter aortic valve implantation
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 279
Beyond survival: determinants of a composite one-year outcome of survival, functional status and cognitive integrity after transcatheter aortic valve implantation
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 274
Age and long-term survival after transcatheter aortic valve implantation: the expected paradox reveals good clinical practice
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 274
Age and long-term survival after transcatheter aortic valve implantation: the expected paradox reveals good clinical practice
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 273
Modified SCORPION technique to mitigate the risk of neo-LVOT obstruction during valve-in-MAC implantation
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 273
Modified SCORPION technique to mitigate the risk of neo-LVOT obstruction during valve-in-MAC implantation
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 263
Three Decades of Heart Transplantation: Survival Trends and Clinical Outcomes in the University Hospital Dubrava Cardiology Cohort
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 263
Three Decades of Heart Transplantation: Survival Trends and Clinical Outcomes in the University Hospital Dubrava Cardiology Cohort
- 1 December 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (1-2) , 39
Valve-in-valve transcatheter aortic valve implantation in a degenerated bioprosthetic aortic valve with severe aortic stenosis and regurgitation: a case report
- 1 December 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (1-2) , 39
Valve-in-valve transcatheter aortic valve implantation in a degenerated bioprosthetic aortic valve with severe aortic stenosis and regurgitation: a case report
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 193
The most important secondary element in transcatheter aortic valve implantation: safe vascular access
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 193
The most important secondary element in transcatheter aortic valve implantation: safe vascular access
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 194
What have we learned from risk scores when selecting patients for transcatheter aortic valve implantation?
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 194
What have we learned from risk scores when selecting patients for transcatheter aortic valve implantation?
- Open Access
- 28 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (2) , 247-260
Comparative 30-day echocardiographic outcomes of Myval vs. Sapien and Evolut THVs: insights from LANDMARK trial
Aims: Several factors, including device design, annulus size, and sizing strategies, influence transcatheter heart valve (THV) haemodynamic outcomes in patients with aortic stenosis (AS). This sub-study evaluates early (30-day) echocardiographic outcomes of the Myval, Sapien, and Evolut THV series, focusing on haemodynamic performance and valve durability. Methods and results: The LANDMARK trial is a prospective, randomised, multicentre, open-label, non-inferiority trial comparing 384 patients implanted with Myval THV series to 384 receiving Sapien and Evolut THV series. Haemodynamic assessments followed Valve Academic Research Consortium-3 recommendations. At 30-day, haemodynamic device success rates were 85.9%, 77.8, and 85.4% for Myval, Sapien, and Evolut THV series, respectively (PMyval-Sapien = 0.03 and PMyval-Evolut = 0.98). Significant improvements in peak aortic flow velocity, pressure gradients, effective orifice area (EOA), Doppler velocity index (DVI), and cardiac indices were observed across all groups, except for unchanged left ventricular ejection fraction. Moderate prosthesis-patient mismatch (PPM) was less frequent with Myval THV series(11.3%) vs. Sapien THV series(21.8%), but higher than Evolut THV series (5.3%) (PMyval-Sapien = 0.0024, PMyval-Evolut = 0.0396), while severe PPM showed no significant differences (4.2% vs. 6.3% vs. 1.8%; PMyval-Sapien = 0.394, PMyval-Evolut = 0.2438). Rates of ≥ moderate paravalvular leak (PVL) were lower in Myval (3.5%), and Sapien (1.7%) compared with Evolut THV series (8.3%) (PMyval-Sapien = 0.3769, PMyval-Evolut = 0.0336). Myval THV series required minimal oversizing compared with Evolut THV series (P < 0.0001). Conclusion: The Myval THV series demonstrates short-term haemodynamic performance comparable to Evolut THV series and superior to Sapien THV series. Including intermediate sizes minimizes oversizing, underscoring its potential as an alternative for TAVI patients. Long-term follow-up is necessary to confirm these findings. Clinical trial registration: ClinicalTrials.gov: NCT04275726, EudraCT number 2020-000,137-40
- 28 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (2) , 247-260
Open AccessComparative 30-day echocardiographic outcomes of Myval vs. Sapien and Evolut THVs: insights from LANDMARK trial
Aims: Several factors, including device design, annulus size, and sizing strategies, influence transcatheter heart valve (THV) haemodynamic outcomes in patients with aortic stenosis (AS). This sub-study evaluates early (30-day) echocardiographic outcomes of the Myval, Sapien, and Evolut THV series, focusing on haemodynamic performance and valve durability. Methods and results: The LANDMARK trial is a prospective, randomised, multicentre, open-label, non-inferiority trial comparing 384 patients implanted with Myval THV series to 384 receiving Sapien and Evolut THV series. Haemodynamic assessments followed Valve Academic Research Consortium-3 recommendations. At 30-day, haemodynamic device success rates were 85.9%, 77.8, and 85.4% for Myval, Sapien, and Evolut THV series, respectively (PMyval-Sapien = 0.03 and PMyval-Evolut = 0.98). Significant improvements in peak aortic flow velocity, pressure gradients, effective orifice area (EOA), Doppler velocity index (DVI), and cardiac indices were observed across all groups, except for unchanged left ventricular ejection fraction. Moderate prosthesis-patient mismatch (PPM) was less frequent with Myval THV series(11.3%) vs. Sapien THV series(21.8%), but higher than Evolut THV series (5.3%) (PMyval-Sapien = 0.0024, PMyval-Evolut = 0.0396), while severe PPM showed no significant differences (4.2% vs. 6.3% vs. 1.8%; PMyval-Sapien = 0.394, PMyval-Evolut = 0.2438). Rates of ≥ moderate paravalvular leak (PVL) were lower in Myval (3.5%), and Sapien (1.7%) compared with Evolut THV series (8.3%) (PMyval-Sapien = 0.3769, PMyval-Evolut = 0.0336). Myval THV series required minimal oversizing compared with Evolut THV series (P < 0.0001). Conclusion: The Myval THV series demonstrates short-term haemodynamic performance comparable to Evolut THV series and superior to Sapien THV series. Including intermediate sizes minimizes oversizing, underscoring its potential as an alternative for TAVI patients. Long-term follow-up is necessary to confirm these findings. Clinical trial registration: ClinicalTrials.gov: NCT04275726, EudraCT number 2020-000,137-40
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 163-164
Large hole no low-flow symptoms
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 163-164
Large hole no low-flow symptoms
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 165
Transcatheter aortic valve implantation following aortic valve repair
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 165
Transcatheter aortic valve implantation following aortic valve repair